Navigation Links
Vanda Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
Date:7/20/2011

ROCKVILLE, Md., July 20, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the second quarter of 2011, on Thursday, August 4, 2011, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Thursday, August 4, 2011.  Also participating on the call will be James Kelly, Senior Vice President and Chief Financial Officer.  To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.

The teleconference dial-in numbers are as follows:

Domestic callers 1-866-314-5232

International callers 1-617-213-8052

Participant Passcode 16117516

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, August 4, 2011, beginning at 1:00 PM ET and will be accessible until Thursday, August 11, 2011, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 57140859.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:
Cristina Murphy
Communications Manager
Vanda Pharmaceuticals Inc.
(240) 599-4500
cristina.murphy@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... , May 20, 2016 ... veteran investors believe that the industry is not far ... and today ActiveWallSt.com featured the following four equities: Anacor ... (NASDAQ: ATHX ), Aralez Pharmaceuticals Inc. (NASDAQ: ... INFI ). Sign up for your free ...
(Date:5/19/2016)... 2016  According to the World Health Organization ... basic diagnostic imaging. Whereas mammography or X-ray are ... States , many places around the world ... the WHO reports that those approximately 4 billion ... death, simply due to the unavailability of radiology. ...
(Date:5/19/2016)... Oregon , May 19, 2016 ... titled, World Medical/Diagnostic Imaging Market -Opportunities and Forecasts, 2015 ... reach $45.0 billion by 2022, registering a CAGR of ... expected to continue to be the highest revenue-generating segment ... accounted for around one-third of the market share ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent heavy flooding in Houston, ... contaminated well water throughout the Houston area. , Heavy floodwaters have led to destroyed ... to contaminants. Residents may not even be aware of the contamination of their water ...
(Date:5/24/2016)... ... May 24, 2016 , ... Aloria Health Announces ... Begin In June , Aloria Health, specializing in a re-imagined, client-oriented approach to ... Milwaukee, its first treatment facility for outpatient, day treatment and residential care. Aloria ...
(Date:5/24/2016)... ... May 24, 2016 , ... Clarion Safety ... safety labels , has been featured in the National Electrical Manufacturers Association’s ... e-newsletter provides electroindustry professionals with manufacturer, regulatory, and standardization news. The publication is ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Since 1946, ... patient-oriented dental care. From the moment a patient arrives at the office, the ... will work with each and every patient to create a complete dental treatment plan ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhysicianOne Urgent Care, advocators in ... tick bites and how to avoid being bitten this spring. , The official ... , Ticks, small spider-like insects, are known for attaching themselves to their prey while ...
Breaking Medicine News(10 mins):